Study on the Effectiveness and Safety of bb2121 Compared to Standard Treatments in Patients with Relapsed and Refractory Multiple Myeloma

Inclusion Criteria

• Must be 18 years or older.
• Must understand and sign a consent form before any study procedures.
• Must be willing to follow the study schedule and requirements, including long-term follow-up if assigned to the bb2121 treatment group.
• Must have a confirmed diagnosis of multiple myeloma with measurable disease.
• Must have received 2 to 4 previous treatments for multiple myeloma.
• Must have been treated with specific drugs in the past and not responded to the last treatment.
• Must have shown some response to at least one previous treatment.
• Must be in good general health with a performance status of 0 or 1.
• Must have recovered from any side effects of previous treatments, except for hair loss and mild nerve damage.
• Must have good blood vessel access for a procedure called leukapheresis.
• Women of childbearing potential must have a negative pregnancy test and agree to use effective birth control.
• Men must agree to use a condom during sexual contact and refrain from donating sperm.
• Must be eligible for one of the standard treatment regimens being compared in the study.

Exclusion Criteria

• Have any serious medical condition or mental illness that would prevent participation.
• Have any condition that poses an unacceptable risk or makes it difficult to interpret study results.
• Have a type of multiple myeloma that does not produce measurable proteins.
• Have certain abnormal lab results, such as low blood cell counts or poor kidney function.
• Have a history of other cancers unless free of disease for 5 years, except for certain skin or cervical cancers.
• Have active or history of certain blood disorders or amyloidosis.
• Have known involvement of the central nervous system with myeloma.
• Have certain lung conditions or severe brain disorders.
• Have received certain treatments recently, such as stem cell transplants or investigational drugs.
• Have a history of severe heart problems or uncontrolled infections.
• Have allergies to any of the study drugs or their components.
• Be pregnant or breastfeeding.
• Be unable or unwilling to follow certain safety measures if assigned to specific treatment regimens.